AVXL (Anavex Life Sciences) Institutional Ownership: 48.60% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVXL Anavex Life Sciences Corp AVXL
26 GF Score
Price $2.34
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Institutional Ownership?

Anavex Life Sciences AVXL -6.40% 26 Institutional Ownership is 48.60% as of Jul. 17, 2026. GuruFocus rates AVXL with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anavex Life Sciences's institutional ownership is 48.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anavex Life Sciences's Insider Ownership is 4.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anavex Life Sciences's Float Percentage Of Total Shares Outstanding is 96.07%.

Anavex Life Sciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Institutional Ownership Chart

Anavex Life Sciences Historical Data

The historical data trend for Anavex Life Sciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 25.22 25.38 24.57 25.47 25.59 25.38 25.69 25.20 25.66 22.92
AVXL
26GF Score
Anavex Life Sciences Corp AVXL
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 48.60% mean?
Anavex Life Sciences (AVXL) has a Institutional Ownership of 48.60% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Institutional Ownership too high?
Anavex Life Sciences' current Institutional Ownership is 48.60%. Overall, Anavex Life Sciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Institutional Ownership compare to SLGL and FATE?
Anavex Life Sciences' Institutional Ownership of 48.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Institutional Ownership is 48.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Institutional Ownership of 48.60%. The current Institutional Ownership is 48.60%. Anavex Life Sciences' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Institutional Ownership is 48.60% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
26GF Score

Get the complete analysis for AVXL

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price